EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Clinical decision support tool‐guided, selective intensive induction strategy of ustekinumab in patients with Crohn's disease: A multicenter cohort study

Qing Li, Jian Tang, Zhao Peng Huang iD, Li Shuo Shi, Xiao Ping Lyu, Xue Min Chen, Wen Ke Chen, An Ying Xun, Qin Guo iD, Miao Li, Xiang Gao iD, Kang Chao iD

Journal of Digestive Diseases · 2024

DOI: 10.1111/1751-2980.13318 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Digestive Diseases, 2024. Verfasst von Qing Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong Province, China. Hauptthemen laut MEDLINE: Crohn Disease, Ustekinumab, Remission Induction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: The Sixth Affiliated Hospital of Sun Yat-sen University Clinical Research-'1010' Program, Key-Area Research and Development Program of Guangdong Province, Program of Guangdong Provincial Clinical Research Center for Digestive Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We aimed to evaluate the effectiveness and safety of clinical decision support tool (CDST)‐guided initial selective intensive induction therapy (IIT) for patients with Crohn's disease (CD) who were treated with ustekinumab (UST) and to identify those most likely to benefit from IIT.

Methods

Patients with active CD were included in this multicenter retrospective study and were categorized as low‐, intermediate‐, and high‐probability responders according to the UST‐CDST. IIT was defined as intensive induction by two or three initial doses of weight‐based intravenous UST administration. Patients treated with standard therapy (ST) served as controls. The primary end‐point was corticosteroid‐free clinical remission (CFCR) at Week 24. Secondary end‐points included clinical remission, clinical response, endoscopic remission, endoscopic response, and C‐reactive protein (CRP) normalization at Week 24. Propensity score adjustments was conducted to ensure comparability.

Results

A total of 296 patients were included. At Week 24, IIT was associated with higher rates of CFCR (72.3% vs 43.0%, p < 0.001), clinical remission (77.3% vs 47.1%, p < 0.001), clinical response (78.1% vs 60.1%, p = 0.001), endoscopic remission (26.1% vs 9.9%, p = 0.024), and endoscopic response (58.6% vs 36.9%, p = 0.018) in low–intermediate‐probability responders compared with ST. CRP normalization was comparable between groups. No significant differences were found in any end‐points in high‐probability responders. No serious adverse events were observed.

Conclusion

The efficacy of IIT was superior to that of ST in patients with predicted poor response to UST, which may be regarded as a novel strategy for stratifying patients at baseline.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseUstekinumabRemission InductionHumansFemaleMaleAdultRetrospective StudiesTreatment OutcomeMiddle AgedDecision Support Systems, ClinicalC-Reactive ProteinInduction ChemotherapyYoung Adult

Stichwörter der Autor:innen

Crohn diseaseclinical decision support toolintensive inductionustekinumab

Substanzen

UstekinumabC-Reactive Protein

Autor:innen und Institutionen

  • Department of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong Province, China.
  • Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong Province, China.
  • Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong Province, China.
  • Center for Clinical Research, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong Province, China.
  • Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
  • Department of Gastroenterology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province, China.

ORCID-Profile: Zhao Peng Huang, Qin Guo, Xiang Gao, Kang Chao

Förderung

  • The Sixth Affiliated Hospital of Sun Yat-sen University Clinical Research-'1010' Program
  • Key-Area Research and Development Program of Guangdong Province
  • Program of Guangdong Provincial Clinical Research Center for Digestive Diseases

Zitieren

APA

Li, Q., Tang, J., Huang, Z. P., Shi, L. S., Lyu, X. P., Chen, X. M., Chen, W. K., Xun, A. Y., Guo, Q., Li, M., Gao, X., & Chao, K. (2024). Clinical decision support tool‐guided, selective intensive induction strategy of ustekinumab in patients with Crohn's disease: A multicenter cohort study. Journal of Digestive Diseases. https://doi.org/10.1111/1751-2980.13318

Vancouver

Li Q, Tang J, Huang ZP, Shi LS, Lyu XP, Chen XM, et al. Clinical decision support tool‐guided, selective intensive induction strategy of ustekinumab in patients with Crohn's disease: A multicenter cohort study. Journal of Digestive Diseases. 2024. doi:10.1111/1751-2980.13318

BibTeX
@article{Li2024,
  author = {Li, Qing and Tang, Jian and Huang, Zhao Peng and Shi, Li Shuo and Lyu, Xiao Ping and Chen, Xue Min and Chen, Wen Ke and Xun, An Ying and Guo, Qin and Li, Miao and Gao, Xiang and Chao, Kang},
  title = {Clinical decision support tool‐guided, selective intensive induction strategy of ustekinumab in patients with Crohn's disease: A multicenter cohort study},
  journal = {Journal of Digestive Diseases},
  year = {2024},
  doi = {10.1111/1751-2980.13318}
}
Kostenlos starten →